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rhytmias with either drug. Side effects were minor with both drugs.
Discussion: The vasoselective calcium antagonist FEL demonstrated equal
efficacy in exercise parameters, and was somewhat superior in quality of life
parameters, if compared to ENA. The massive vasodilation induced by FEL,
as demonstrated by the RPP was not accompanied by an activation of the
neurohormonal system, so often observed with other vasodilating agents.
Conclusion: FEL can be seriously considered as an alternative treatment
for ACEI in CHF patients. A direct comparison between FEL and ACEI in CHF,
with special emphasis on long term efficacy and mortality seems of interest.
Placebo Bisoprolol p
10th perc (ms) 58± 18 64 ± 30 NS
25th perc (ms) 95± 35 101 ± 35 NS
50th perc Ims) 133 ± 43 152 ± 37 0.02
75th perc Ims) 134 ± 53 171 ± 53 0004
90th perc Ims) 120± 12 139 ± 46 005
In conclusion, HRV is not improved at higher heart rates. On the contrary,
these results indicate that low dose Bisoprolol improves short term HRV at
lower heart rates in CHF
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Multiple drug therapy, including ACE inhibitors, diuretics, vasodilators and
digoxin is currently used to reduce signs and symptoms of chronic heart fail-
ure (CHF). Optimal treatment of these patients (pts) is a major clinical prob-
lem, as the prevalence of CHF increases. Ibopamine, a novel oral dopamine
agonist with peripheral vasodilating and neurohumoral inhibiting effects,
may have additive value in the treatment of pts with moderately severe CHF,
already treated with ACE-inhibitors.
To evaluate the additive value of ibopamine as adjunctive to maximal CHF
treatment we studied 60 pts with NYHA class III-IV CHF, who were assigned
to treatment with ibopamine (3 dd 100 mgl or placebo in a double-blind,
randomized fashion.
We examined the effect of ibopamine on peak oxygen consumption (V02),
neurohumoral factors and cardiac arrhythmias during 48 hrs ECG monitoring.
Neurohumoral parameters were determined at rest and during exercise and
included serum norepinephrine, epinephrine, aldosterone and plasma renin
activity. All assessments were made at baseline and after 12 weeks of study
treatment.
Baseline data: Of the 60 pts, 40 pts (67%) had ischemic heart disease
andlor old myocardial infarction, and 20 (33%) non-ischemic heart disease
(16 pts (27%) dilated myocardiopathy). Mean age was 63 ± 10 years, left
ventricular ejection fraction 0.23 ± 0.08, peak V02 15.0 ± 2.4 mllminlkg and
44 of the patients (73%) were male. Background CHF therapy included ACE-
inhibitors (100%), diuretics (100%), and digoxin, nitrates, amiodarone when
required. At baseline resting serum norepinephrine was 724 ± 78 pglml,
epinephrine 68 ± 17 pglml, aldosterone 0.50 ± 0.08 nmolll and plasma renin
aClivity 5.7 ± 0.9 ng/mllhr.
Results: The study was recently completed, the study data are currently
analyzed and the results will be presented at the meeting.
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Placebo-controlled Study
William A. Anderson, Deborah A. IIkowski, Javier Fernandez, Glenn W. Laub, Mark
S. Adkins, Chao Chen, Lynn B. McGrath. Deborah Heart and Lung Center, Browns
Mil/s,NJ
From 1983 to 1992,203 patients with preoperative symptoms of chronic CHF
and not angina underwent primary CABG for ischemic cardiomyopathy. This
represented 3% of all patients undergoing CABG, however, this figure rose
to 8% over the last two years of the study. Patients with valvular lesions,
left ventricular aneurysms or those with acute post infarction heart failure
were excluded. The mean age was 67 years and 63% of the patients were
male. 92% of the patients were in NYHA Class III or IV prior to undergo-
ing CABG. The mean preoperative ejection fraction was 34% ± 13% and the
mean LVEDPwas 20.7 mmHg ± 8.4 mmHg. A LIMA graft was used in 68% of
the patients. Follow-up was 98% complete. The hospital mortality was 6.0%
and the actuarial survival at 5 years was 59%. An improvement in NYHA class
occurred in 75% of the surviving patients with a mean improvement of 1.6
± 0.6 NYHA classes; 18% of the survivors remained the same and 7% were
worse. Univariate analysis identified risk factors for hospital death as emer-
gency operation, recent myocardial infarction «30 days), the need for IABP
and non use of a LIMA graft. Use of the LIMA did predict late survival (p ~
0.02), however did not affect NYHA class in the surviving patients. We con-
clude that CABG is effective in ameliorating symptoms of chronic congestive
heart failure in patients suffering from chronic ischemic cardiomyopathy and
can be performed with acceptable early and late mortality.
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Patients with congestive heart failure (CHF) have reduced heart rate variability
(HRV). Beta-blockers (BB) therapy could improve HRV in CHF However, HRV
is influenced by heart rate. The aim of our study was to assess the effect of
BB on heart rate adjusted-HRV in 52 patients from the randomized, double-
blind, placebo-controlled CIBIS trial (Cardiac Insufficiency Bisoprolol Study).
After progressive increase, Bisoprolol was 5 mg once a day. Holter tapes
were recorded at baseline and after 2 months of therapy. To assess HRV at
given heart rates, we developed a geometrical analysis of scatterplots (SCP).
SCP display beat-ta-beat HRV by plotting each RR against the preceding RR
interval. SCP heigth, a measure of short term HRV, was measured at the
10th, 25th, 50th, 75th and 90th percentiles of the total RR dispersion (figure).
The 10th percentile represents the fastest hearts rates, whereas the 90th
represents the slowest heart rates. There was no significant difference in
baseline SCP measurements. Results of BB therapy on SCP heights are as
follow (mean ± SD):
Michele A. Hamilton, Lynne W. Stevenson, Gregg C. Fonarow, Anthony E. Steimle,
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Thyroid hormone metabolism is frequently abnormal in patients with ad-
vanced congestive heart failure (CHF), with low triiodothyronine (13) levels
associated with poor hemodynamics and increased mortality. Studies have
suggested that intravenous (Lv.) T3 improves hemodynamics acutely in pa-
tients immediately post-bypass surgery. To assess the safety of i.v. 13 (which
may have unique inotropic mechanisms) in CHF, 22 patients with class III or
IV CHF were given an Lv. 13 bolus ±6 hour infusion (total dose range 0.05
- 1.7 /.<glkg) under hemodynamic and ECG monitoring. Basal metabolic rate
(BMR) by indirect calorimetry and LVEF by echo were measured at baseline
and 2-4 hours post dosing.
Results: No patient had angina or sustained supraventricular or ventricular
ectopy and mean heart rate (HR) did not change significantly (94 ± 16 to 98 ±
13 bpm, p = NS), with only 3/22 patients having an increase in HR > 10 bpm.
There was no significant change in mean BMR (2221 ± 899 to 2449 ± 682
Kcal/day, p = NS) and only minimal change in mean core temperature (36.8
± 0.4 to 37.3 ± 0.6°C, P = 0.007), reflecting a peak temperature 38.0-38.5°
C in 4 patients. Cardiac output increased by > 1.0 Umm in 11/22 patients
(>50% increase over baseline in 8/22 patients) with no significant change in
LVEF (22 ± 7 to 23 ± 6%, P = NS) or filling pressures.
Conclusion: Acute intravenous T3 administration is well tolerated in pa-
tients with advanced CHF and has potential hemodynamic benefit warrant-
ing further investigation.
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Differential Effect of Bisoprolol on Heart Rate
Variability According to Heart Rate In Patients
with Heart Failure
